As one of the leading companies invested in stem cell research, Celixir is instrumental in researching and pioneering new and innovative ways to use stem cells, in order to advance medicine, in particular, patient care.

 

From the moment the first human embryonic stem cells were grown in a laboratory, scientists have worked hard to research whether stem cells could be used to repair damaged tissue or even grow new organs. And as this pioneering research continues, several breakthroughs along the way have occurred. 

What have Celixir themselves been working on?

For starters, Celixir is extremely proud of their Heartcel™ research. A novel, off the shelf regenerative therapy treatment for myocardial regeneration, targeting patients who suffer from ischaemic heart disease, who are going to be undergoing coronary artery bypass graft. 

 

More specifically, Heartcel™ targets those patients who have just a 30% survival rate at 1 year. This treatment is currently the focus of a Phase IIb human clinical trial due to be completed in 2020, being held at Imperial College London’s Royal Brompton, UK.

 

But that isn’t the only stem cell treatment Celixir is researching at the moment. Innovation is what drives this world-class team of scientists and biotech engineers, and their unique technology platform enables some incredible in-house discoveries, resulting in the manufacturing of new medicines. 

 

Presently, the team at Celixir are looking into over 20 tissue-specific regenerative medicines that could be used to advance modern medicine, and bring about some much-needed change to current patient healthcare. 

 

Having only been around for just a decade, the advances that Celixir have made and the research that they’re involved in is unprecedented in their field of regenerative medicine. 

Celixir R&D activity

As well as Heartcel™, R&D activities that Celixir are working on to bring life-saving regenerative medicines to the market also include Tendoncel – a platelet lysate-based therapy. 

 

The team working on this stem cell research are investigating whether a topical gel that contains platelet lysate is capable of regenerating injured tendons that are located near to the surface of the skin. At the moment, this research is undergoing phase 3 of a trial into tennis elbow. 

 

The team at Celixir are also undergoing research into Myocardion – a progenitor cells of mesodermal lineage (PML) therapy. This research is clinical trial-ready and PML cells are being looked into as a potential treatment for patients suffering with mild to moderate heart failure. 

 

Whilst Celixir are leading the charge with their continuing breakthroughs in stem cell research, they are not alone in their work. Because without continual breakthroughs, medicine would stagnate, patient healthcare would suffer and incurable diseases would remain just so. 

 

So what other developments in stem cell research have occurred in the three decades since scientists first discovered how to derive embryonic stem cells from mouse embryos way back in 1981?

10 breakthroughs in stem cell research

    1. 1981 – Nobel Laureate (and co-founder of Celixir), Sir Martin Evans first identifies embryonic stem cells in mice.
    2. 1989 – the first ‘knockout’ mice are created allowing scientists to find out which genes are responsible for which diseases. 
    3. 1997 – the first artificial animal clone is unveiled to the world in the form of Dolly the Sheep, leading scientists to speculate that similar results could occur if human embryonic stem cells were fused with adult cells, in order to create genetically identical tissue and organs. 
    4. 1998 – the first human embryonic stem cells are created in a laboratory, allowing scientists to learn more about how certain cells function. 
    5. 2002 – human embryonic stem cells are turned into heart muscle cells, leading scientists to explore if new heart muscle could be grown for patients with heart failure. 

  • 2006 first induced pluripotent stem cells are revealed in Japan – they’re a way to make embryonic-like stem cells from adult cells, avoiding the need to use embryonic stem cells for research. 

 

  1. 2010 – a patient with a spinal injury is the first person to receive medical treatment stemming from human embryonic stem cells as part of a trial by Geron, California. 
  2. 2012 – blindness is shown to be reversible with human embryonic stem cells. 
  3. 2014 – therapeutic cloning with adult cells is shown to work. 
  4. 2018 – Heartcel™ is given the green light for heart failure trial to be completed in 2020, with potential market entry in 2021.

 

Categories: Stem Cells

0 Comments

Leave a Reply

Your email address will not be published. Required fields are marked *